When was Genomics founded?

Genomics was founded in 2014 and raised its 1st funding round within a year of its incorporation.

Where is Genomics located?

Genomics is headquartered in Oxford, United Kingdom. It is registered at King Charles House, Park End Street, Oxford, United Kingdom, OX1 1JD.

Who is the current CEO of Genomics?

Peter Donnelly of Genomics. They have also founded 1 company.

Which legal entities is Genomics associated with?

Genomics is associated with Genomics Plc.

How many employees does Genomics have?

As of Feb 28, 2026, the latest employee count at Genomics is 197.

Is Genomics a funded company?

Genomics is a funded company, having raised a total of $146M across 11 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Apr 15, 2014.

When was the latest funding round of Genomics?

Genomics' latest funding was a $***** Series C round on Jan 08, 2024, with participation from 4 investors. Its primary sector is Genomics. Globally, the Genomics sector has seen $500M in funding in 2026 to date.

Where does Genomics rank among its competitors?

Genomics ranks 34th amongst 377 active competitors, of which 125 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Evotec, which secured an undisclosed amount in Jan, 2026.

Who are the top competitors of Genomics?

Genomics' top competitors include Human Longevity, Evotec and Juno Therapeutics. Among them, Evotec secured the most recent funding round in January, 2026.

Genomics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of genomic risk assessment and prevention platform. This platform uses advanced polygenic risk scores and data science to predict individual risk of common diseases. It offers personalized tools and guidance for individuals, employers, and healthcare providers. The platform also assists life sciences companies in accelerating drug discovery and optimizing clinical trial design. The company's work contributes to more personalized and precise healthcare, ultimately aiming to improve health outcomes and reduce the cost of common diseases.

Website: www.genomics.com/
Email ID: *****@genomics.com, *****@genomics.com, *****@genomics.com, *****@insightsgenomics.com, *****@genomics.com, *****@genomics.com
Phone Number: +44 **********
Registered Address: King Charles House, Park End Street, Oxford, United Kingdom, OX1 1JD

Key Metrics

Founded Year

2014

Location

Oxford, United Kingdom

Stage

Series C

Total Funding

$146M in 11 rounds

Latest Funding Round

Series C, Jan 08, 2024, $*****

Investors

Foresite Capital & 18 more

Ranked

34^th among 377 active competitors

Employee Count

197 as on Feb 28, 2026

Similar Companies

Human Longevity & 514 more

View Genomics' full profile

Genomics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Genomics Plc CIN: 8839972 , United Kingdom, Active	Jan 09, 2014	$7.01M (As on Dec 31, 2023)	83 (As on Jan 31, 2021)

Genomics has raised a total funding of $146M over 11 rounds. Its first funding round was on Apr 15, 2014. Its latest funding round was a Series C round on Jan 08, 2024 for $*****. 4 investors participated in its latest round. Genomics has 19 institutional investors.

Here is the list of recent funding rounds of Genomics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 08, 2024	8309123	Series C	7019271	6167955	5092291	9933358
Mar 01, 2021	2214709	Series B	7489921	1505591	6894162	Oxford Science Enterprises & 1 more
Dec 10, 2018	1398654	Series B	1815676	9028265	Foresite Capital	F-Prime Capital & 7 more

Access funding benchmarks and valuations. Sign up today!

View details of Genomics's funding rounds and investors

The founders of Genomics are Peter Donnelly and Gil McVean. Peter Donnelly is the CEO of Genomics.

Here are the details of Genomics' key team members:

Peter Donnelly: Co-Founder & CEO of Genomics.
Gil McVean: Co Founder & Director of Genomics.

View details of Genomics's Founder profiles and Board Members

Genomics' employee count trend

Genomics has 197 employees as of Feb 26. Here is Genomics's employee count trend over the years:

Uncover Genomics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Genomics include Human Longevity, Evotec and Juno Therapeutics. Here is the list of Top 10 competitors of Genomics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Human Longevity 2013, San Diego (United States), Series B	Provider of precision medicine, preventative health assessments, and longevity care	$409M	Celgene, General Electric & 20 others	76/100
2nd	Evotec 1993, Hamburg (Germany), Public	Provider of drug discovery alliance and development services for biopharma sector	$25M	TVM Capital Life Science, Mubadala & 20 others	76/100
3rd	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	RA Capital Management, BB Biotech & 14 others	74/100
4th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	74/100
5th	DNAnexus 2009, Mountain View (United States), Series H	Provider of cloud-based genome informatics & data management platform	$473M	Google Ventures, TPG & 21 others	70/100
6th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
7th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Foresite Capital, Advent Life Sciences & 11 others	70/100
8th	Orchard Therapeutics 2015, London (United Kingdom), Acquired	Developer of gene therapies for treating rare diseases	$440M	Baillie Gifford, ORI Capital & 30 others	70/100
9th	Castle Biosciences 2008, Friendswood (United States), Public	Provider of diagnostic devices for treating cancer	$62M	Industry Ventures, Health Quest Capital & 9 others	70/100
10th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Third Rock Ventures & 9 others	70/100
34th	Genomics 2014, Oxford (United Kingdom), Series C	Provider of genomic risk assessment and prevention platform	$146M	Invesco Mutual Fund, Foresite Capital & 17 others	58/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Genomics's competitors? Click here to see the top ones

Founders own 14.90%, Funds own 10.00%, Enterprises (largest shareholder) own 20.20% and Angels own 5.30%. The net worth of Genomics's founders is INR 15.4M as of Feb 17, 2020.

Shareholders Name	Post Round Holding %	Net worth	Cumulative Investment	Realised Returns	Unrealised Returns	Return Multiple
Founder	14.90%	15.4M	3443297	2595758	5855322	1552948
Fund	10.00%	10.2M	6394470	7159379	4027601	2471261
Foresite Capital	53954	62117	37709	50943	45133	20193
F-Prime Capital	47029	82320	26214	62923	15777	46470
Enterprise	20.20%	20.9M	2763380	8513656	2272152	6727171
Angel	5.30%	5.49M	50788	92502	49432	66447
Other People	3.04%	3.16M	893	731	440	607
Total	53.44%	5.52Cr	4386539	6349476	1276487	7792222